Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

• Status: Completed
• Trial end date: 2002-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Hemostatics

Criteria

Inclusion Criteria:

• Patients with the clinical diagnosis of Dengue Haemorrhagic Fever (DHF)

• Patients with a clinical diagnosis of DHF Grades II and III8, requiring standard replacement therapy

Exclusion Criteria:

• Patients with a clinical diagnosis of DHF Grade IV

• Known or suspected allergy to trial product or related products

• Known hypersensitivity to mouse, hamster or bovine protein

• Prior treatment with activated recombinant human factor VII